Association of BRAFV600E mutation with clinicopathological features of papillary thyroid carcinoma: A study on a Chinese population

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 10, 2014, Pages 6922-6928

  Liu, Shu ^a   Zhang, Bingfei ^a   Zhao, Yanru ^a   Chen, Pu ^a   Ji, Meiju ^a   Hou, Peng ^a   Shi, Bingyin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Papillary thyroid carcinoma (PTC); Percentage of BRAFV600E alleles; Preoperative risk stratification; Pyrosequencing

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA; CHINA; ENZYMOLOGY; EPIDEMIOLOGY; ETHNOLOGY; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; HUMAN; MALE; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; PROGNOSIS; THYROID NEOPLASMS; TUMOR INVASION;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BIOPSY, FINE-NEEDLE; CARCINOMA; CHINA; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS;

EID: 84912079167     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE and Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic eviTable dence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003; 63: 1454-1457.
2. Xu X, Quiros RM, Gattuso P, Ain KB and Prinz RA. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 2003; 63: 4561-4567.
3. Liu S, Gao A, Zhang B, Zhang Z, Zhao Y, Chen P, Ji M, Hou P, Shi B. Assessment of molecular testing in fine-needle aspiration biopsy samples: An experience in a Chinese population. Exp Mol Pathol 2014; 97: 292-297.
4. Tufano RP, Teixeira GV, Bishop J, Carson KA and Xing M. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine (Baltimore) 2012; 91: 274-286.
5. Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, Shibru D, Bastian B and Griffin A. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 2007; 246: 466-470; discussion 470-461.
6. Lim JY, Hong SW, Lee YS, Kim BW, Park CS, Chang HS and Cho JY. Clinicopathologic implications of the BRAFV600E mutation in papillary thyroid cancer; a subgroup analysis of 3130 cases in a single center. Thyroid 2013; 23: 1423-30.
7. Pelizzo MR, Boschin IM, Barollo S, Pennelli G, Toniato A, Zambonin L, Vianello F, Piotto A, Ide EC, Pagetta C, Sorgato N, Torresan F, Girelli ME, Nacamulli D, Mantero F and Mian C. BRAF analysis by fine needle aspiration biopsy of thyroid nodules improves preoperative identification of papillary thyroid carcinoma and represents a prognostic factor. A mono-institutional experience. Clin Chem Lab Med 2011; 49: 325-329.
8. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D and Ladenson PW. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005; 90: 6373-6379.
9. Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, Maximo V, Botelho T, Moreira S, Meireles AM, Magalhaes J, Abrosimov A, Cameselle-Teijeiro J and Sobrinho-Simoes M. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch 2005; 446: 589-595.
10. Puxeddu E, Moretti S, Elisei R, Romei C, Pascucci R, Martinelli M, Marino C, Avenia N, Rossi ED, Fadda G, Cavaliere A, Ribacchi R, Falorni A, Pontecorvi A, Pacini F, Pinchera A and Santeusanio F. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 2004; 89: 2414-2420.
11. Liu RT, Chen YJ, Chou FF, Li CL, Wu WL, Tsai PC, Huang CC and Cheng JT. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clin Endocrinol (Oxf) 2005; 63: 461-466.
12. Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J and Garcia-Rostan G. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2008; 68: 618-634.
13. Ito Y, Yoshida H, Maruo R, Morita S, Takano T, Hirokawa M, Yabuta T, Fukushima M, Inoue H, Tomoda C, Kihara M, Uruno T, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F and Miyauchi A. BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J 2009; 56: 89-97.
14. Grogan RH, Kaplan SP, Cao H, Weiss RE, Degroot LJ, Simon CA, Embia OM, Angelos P, Kaplan EL and Schechter RB. A study of recurrence and death from papillary thyroid cancer with 27 years of median follow-up. Surgery 2013; 154: 1436-1446; discussion 1446-1437.
15. Guerra A, Sapio MR, Marotta V, Campanile E, Rossi S, Forno I, Fugazzola L, Budillon A, Moccia T, Fenzi G and Vitale M. The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma. J Clin Endocrinol Metab 2012; 97: 517-524.
16. Guerra A, Fugazzola L, Marotta V, Cirillo M, Rossi S, Cirello V, Forno I, Moccia T, Budillon A and Vitale M. A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome. J Clin Endocrinol Metab 2012; 97: 2333-2340.
17. Xing M. Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol 2010; 321: 86-93.
18. Giovagnoli MR, Pisani T, Drusco A, Scardella L, Antonaci A and Vecchione A. Fine needle aspiration biopsy in the preoperative management of patients with thyroid nodules. Anticancer Res 1998; 18: 3741-3745.
19. Hanni CL, Bratt HJ, Dean RE and Vanvliet PD. Fine needle aspiration biopsy. A reliable diagnostic tool in the management of thyroid nodules. Am Surg 1984; 50: 485-487.
20. Al-Shaikh A, Ngan B, Daneman A and Daneman D. Fine-needle aspiration biopsy in the management of thyroid nodules in children and adolescents. J Pediatr 2001; 138: 140-142.
21. Yeo MK, Liang ZL, Oh T, Moon Y, An S, Kim MK, Kim KS, Shong M, Kim JM and Jo YS. Pyrosequencing cut-off value identifying BRAFV600E mutation in fine needle aspiration samples of thyroid nodules. Clin Endocrinol (Oxf) 2011; 75: 555-560.
22. Fugazzola L, Mannavola D, Cirello V, Vannucchi G, Muzza M, Vicentini L and Beck-Peccoz P. BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf) 2004; 61: 239-243.
23. Sancisi V, Nicoli D, Ragazzi M, Piana S and Ciarrocchi A. BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas. J Clin Endocrinol Metab 2012; 97: E1745-1749.
24. Xing M. BRAF V600E mutation and papillary thyroid cancer--in reply. JAMA 2013; 310: 534-535.
25. Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O'Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Tufano RP, Pai SI, Zeiger MA, Westra WH, Clark DP, Clifton-Bligh R, Sidransky D, Ladenson PW and Sykorova V. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 2013; 309: 1493-1501.